News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Videos|March 11, 2021

Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

Author(s)Diana Castro, MD, Garey H. Noritz, MD

Garey H. Noritz, MD, walks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Episodes in this series

EP. 1 Pediatric Neurological Exam to Identify SMA

EP. 1 Pediatric Neurological Exam to Identify SMA

EP. 2 Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

EP. 2 Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

EP. 3 Referral of SMA to a Neurologist

EP. 3 Referral of SMA to a Neurologist

EP. 4 Newborn Screening for SMA

EP. 4 Newborn Screening for SMA

EP. 5 Signs and Symptoms of SMA

EP. 5 Signs and Symptoms of SMA

EP. 6 Evaluation of Suspected SMA via In-Person and Remote Exam

EP. 6 Evaluation of Suspected SMA via In-Person and Remote Exam

EP. 7 Discussing the Diagnosis of SMA With the Family

EP. 7 Discussing the Diagnosis of SMA With the Family

EP. 8 SMA Resources for Physicians and Families

EP. 8 SMA Resources for Physicians and Families

EP. 9 Telehealth During COVID-19

EP. 9 Telehealth During COVID-19

EP. 10 Importance of Follow-Up Visits for SMA Amid COVID-19

EP. 10 Importance of Follow-Up Visits for SMA Amid COVID-19

EP. 11 Advice to Community Neurologists Treating SMA

EP. 11 Advice to Community Neurologists Treating SMA

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

NeurologyLive® Brain Games: September 13, 2026

ByLouie Pasculli,Marco Meglio

Published: September 13th 2026 | Updated: September 10th 2026

What's New in Stroke Rehabilitation and Recovery: An FAQ on the AHA/ASA Guideline

September 12th 2026

Case Report Reveals Rare EBV-Driven Complication of Long-Term Mycophenolate Use in AQP4+ NMOSD

ByIsabella Ciccone, MPH

September 12th 2026

AAN, AHS Issue Updated Guideline on Migraine Prevention, Atogepant Meets End Points in Phase 3 Trial, Trientine Enters Phase 3 Trial

ByNeurologyLive® Staff

September 12th 2026

FDA Approves Apitegromab for Spinal Muscular Atrophy

ByLouie Pasculli

September 11th 2026

Latest CME

2026 Carolina Neuromuscular Disease Summit

In-Person + Virtual Event

2026 Carolina Neuromuscular Disease Summit

September 19-20, 2026

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

In-Person Event

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

Primary Care Education in Nashville

In-Person + Virtual Event

Primary Care Education in Nashville

October 20-21, 2026

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Show Me the Data™: Turning Molecular Drivers Into Precision Care for CNS Tumors

In-Person + Virtual Event

Show Me the Data™: Turning Molecular Drivers Into Precision Care for CNS Tumors

November 12, 2026

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Apitegromab for Spinal Muscular Atrophy

AAN, AHS Issue Updated Guideline on Migraine Prevention, Atogepant Meets End Points in Phase 3 Trial, Trientine Enters Phase 3 Trial

CGRP-Therapy Atogepant Meets Primary and Secondary End Points in Phase 3 LUNA Trial for Menstrual Migraine

Exploring the Link Between Football Players and ALS: Rory Siegel, DO

AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs